These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21652233)

  • 1. Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?
    Kawashima H; Inokuchi M; Furukawa H; Kitamura S
    Acad Radiol; 2011 Aug; 18(8):963-9. PubMed ID: 21652233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy.
    Javid S; Segara D; Lotfi P; Raza S; Golshan M
    Ann Surg Oncol; 2010 Jul; 17(7):1841-6. PubMed ID: 20143266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary sentinel node biopsy after neoadjuvant chemotherapy.
    Ozmen V; Unal ES; Muslumanoglu ME; Igci A; Canbay E; Ozcinar B; Mudun A; Tunaci M; Tuzlali S; Kecer M
    Eur J Surg Oncol; 2010 Jan; 36(1):23-9. PubMed ID: 19931375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Li SP; Taylor NJ; Makris A; Ah-See ML; Beresford MJ; Stirling JJ; d'Arcy JA; Collins DJ; Padhani AR
    Radiology; 2010 Dec; 257(3):643-52. PubMed ID: 20858850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Tsunoda-Shimizu H; Hayashi N; Hamaoka T; Kawasaki T; Tsugawa K; Yagata H; Kikuchi M; Suzuki K; Nakamura S
    Breast Cancer; 2008; 15(2):133-40. PubMed ID: 18288570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
    Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
    Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy after neoadjuvant systemic chemotherapy in patients with breast cancer: a prospective pilot trial.
    Medina-Franco H; Salgado-Nesme N; Zerón-Medina-Cuairán J
    Rev Invest Clin; 2008; 60(5):390-4. PubMed ID: 19227436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.
    Tanaka Y; Maeda H; Ogawa Y; Nishioka A; Itoh S; Kubota K; Ue H; Nakatani K; Sasaguri S
    Oncol Rep; 2006 Apr; 15(4):927-31. PubMed ID: 16525681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.
    Rubio IT; Aznar F; Lirola J; Peg V; Xercavins J
    Ann Surg Oncol; 2010 Jan; 17(1):235-9. PubMed ID: 19777186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.